Physician profile
Joseph B Felder
NPI 1174522569
$4,544.67
in general payments reported to CMS, 2019-2025
32 companies · $514 in 2025
The $514 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $467 · 2020: $309 · 2021: $812 · 2022: $697 · 2023: $800 · 2024: $946 · 2025: $514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,238 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,237.68 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,148.45 | 2019-2025 | |
| Qol Medical, LLC | $435.46 | 2019-2024 | Sucraid, Sucraid |
| Celgene Corporation | $404.73 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $319.83 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $318.97 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $274.75 | 2019-2025 | Xifaxan |
| Ferring Pharmaceuticals INC. | $232.94 | 2019-2022 | |
| Pfizer INC. | $174.93 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $166.53 | 2024 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $154.78 | 2023-2025 | Dupixent |
| Novo Nordisk INC | $120.75 | 2023-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $98.61 | 2023-2025 | Mounjaro, Omvoh, Zepbound |
| Glaxosmithkline, LLC. | $83.16 | 2019-2022 | |
| Braintree Laboratories, INC. | $78.51 | 2021-2024 | Suflave, Sutab |
| Ironwood Pharmaceuticals, INC | $61.29 | 2020-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $56.49 | 2024-2025 | Vegzelma |
| Redhill Biopharma INC. | $55.96 | 2020-2023 | Talicia, Movantik, Aemcolo |
| Ardelyx, INC. | $55.66 | 2025 | Ibsrela |
| Allergan, INC. | $46.88 | 2019 | |
| Sandoz INC. | $34.93 | 2023-2024 | Hyrimoz |
| Intercept Pharmaceuticals, INC. | $30.22 | 2021 | |
| Genzyme Corporation | $24.57 | 2022 | |
| Evoke Pharma, INC. | $22.86 | 2023 | Gimoti |
| Vbi Vaccine (Delaware) INC. | $22.72 | 2023 | Prehevbrio |
| Romark Laboratories, Lc | $21.87 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.11 | 2023 | Cyltezo |
| Genentech USA, INC. | $18.53 | 2019 | |
| Capsovision, INC. | $18.37 | 2023 | Capsocam Plus |
| Olympus America INC. | $17.19 | 2025 | Olympus |
| Medtronic USA, INC. | $12.92 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.70 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Felder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.